The Mayo Clinic has launched an emergency clinical trial of a novel way of treating urinary tract infections (UTIs) in the UK.

The trial, dubbed ‘Eve, the medicine’, is being conducted by the Mayo Clinic Research Institute (MCRI) in collaboration with the University of Warwick and Covid-19 Research Centre.

The goal is to find a new treatment that will reduce the rate of UTIs in a family, in which up to 90 per cent of patients have no symptoms.

Eve will be administered in a single dose in a hospital setting, the researchers said.

The researchers are currently recruiting patients to participate in the trial, and are hopeful the drug will have an impact in the near future.

“The drug could potentially be the first clinical trial in which a drug has shown effectiveness against UTIs, as well as other infectious diseases such as HIV, and in patients with COPD,” said Dr Joanne Gildersleeve, director of the MCRI’s Centre for Infectious Diseases and Nephrology.

“If it is successful, this will have huge implications for infectious disease research in the country and could help to accelerate the development of new treatments for UTIs.”

The first batch of eight patients who will receive the drug, the team said, will have their urine tests taken within three days of receiving the treatment.

The drug will be delivered by a pill which is manufactured in China, and is currently in Phase II trials, and will be available for patients in the United Kingdom, Australia and New Zealand.

The team said the drug has already shown “significant efficacy in reducing the risk of UTI recurrence and infection”.

The drug, called ‘EVE’, was approved in 2013.

The new drug is a synthetic form of the drug called Covid, which causes UTIs.

It works by blocking the transmission of the virus from a person to another person by preventing the virus being made in the body.

“Eve is one of the few drugs that can target Covid,” said lead researcher Dr Annette Ritchie, from Covid Research Centre, Covid UK.

“It is a new approach to treating UTIs by preventing its entry into the body.””EVE has shown remarkable efficacy in patients in Phase I trials with lower risk of recurrence of UTAs compared to the previous Covid therapies.”

The new trial will include 20 patients, and the results of the trial will be made public in the coming months.

This news comes just a few weeks after Covid was reported to be the most dangerous infectious disease in the world.

It has been linked to more than 10,000 deaths and over 6,000,000 cases in the US alone, and has infected more than 1,000 people in the last two years.

The UK has suffered more than 700 deaths from the virus in the past 12 months, with another 3,000 confirmed cases and the highest number of deaths among the 28 countries that have agreed to phase out Covid.

In October, Covide was approved by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), the UK government’s healthcare regulator.

The agency has said that Covid can no longer be used to treat the UK, but that it will continue to recommend that people who are suffering from the disease get the drug.